We use cookies to ensure that we give you the best experience on our website Learn more
Home
Saved research
2
Views
2
Views
Fullscreen
Apr 1, 2016
26th European Congress of Clinical Microbiology and Infectious DiseasesLow rates of severe injection-site and systemic adverse events within 7 days post-vaccination with ZOSTAVAX™, a post hoc analysis of two pivotal phase 3 trials
;Zoran Popmihajlov;
Lei Pang;
Elizabeth Brown;
Shu-Chih Su;
Susan Kaplan;
English Willis
zoster vaccine live
shingles vaccine
zostavax
herpes zoster
vaccine
2
Views
2
Views
Fullscreen
Oh no! This abstract is missing. Is this your research? Get in touch at support@morressier.com
Keywords
zoster vaccine live
shingles vaccine
zostavax
herpes zoster
vaccine
Company
Legal
Follow us
© Copyright 2019 Morressier GmbH. All rights reserved.